Auna (AUNA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
Revenue grew 13% year-over-year to S/1,238 million, with all segments contributing to growth and strong demand for high-complexity services.
Adjusted EBITDA declined 6% YoY to S/227 million (down 9% FX neutral), with margin at 18.4%, reflecting temporary margin pressures, service mix changes, and billing penalties in Peru.
Free cash flow surged 181% YoY, and cash position rose 43% since year-end 2025, highlighting strong cash management.
Leverage ratio improved to 3.6x, with further reductions targeted by year-end.
Net income was S/33 million, down from S/84 million in 2Q25, mainly due to lower non-cash FX gains.
Financial highlights
Revenue: S/1,238 million (+13% YoY, +9% FXN YoY).
Adjusted EBITDA: S/227 million (-6% YoY, -9% FXN YoY), margin 18.4%.
Adjusted net income: S/40 million; net income: S/33 million; adjusted EPS: S/0.50.
Operating cash flow: S/441 million YTD (+45% YoY); free cash flow: S/400 million YTD (+181% YoY).
Gross margin: 36.2% in Q2 2026, down 4.0 p.p. YoY.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at ~12% FX-neutral growth.
Adjusted EBITDA growth expected at the low end of the 10%-14% range, excluding Peru billing penalties.
Free cash flow projected to exceed internal expectations, supporting a leverage ratio target below 3.0x.
Margin recovery anticipated in Colombia in 2H 2026 as price adjustments offset wage increases.
Sequential improvements anticipated in Mexico and Colombia as cost pressures normalize.
Latest events from Auna
- Revenue up 13% YoY, strong cash flow, margin down, guidance reaffirmed.AUNA
Q1 2026 - FY25 saw strong cash flow, Peru and Colombia growth, and a 12% FXN growth target for 2026.AUNA
Q4 2025 - Healthcare group targets $1B NYSE offering to expand Latin American operations.AUNA
Registration Filing - Healthcare group seeks up to $1B in NYSE-listed shares to fund growth in Latin America.AUNA
Registration Filing - Peru and Colombia drove growth, Mexico lagged; leverage stable, refinancing and recovery plans set.AUNA
Q3 2025 - Adjusted EBITDA up 23% YoY, leverage ratio at 3.7x, and OncoMexico pilot advancing.AUNA
Q3 2024 - Adjusted EBITDA up 31% YoY, revenue up 18% YoY, and leverage ratio improved to 4.13x.AUNA
Q2 2024 - Peru's growth offset Mexico and Colombia's declines, sustaining profitability and stable leverage.AUNA
Q1 2025 - FY24 Adjusted EBITDA up 20.1% FXN, margin and net income improved, leverage at 3.6x.AUNA
Q4 2024